$BFRI SEC Filings

Filed On	Filing
14 Sep 2026	8-K: Other Events Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy plat...
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
12 Aug 2026	SCHEDULE 13G/A
29 Jul 2026	Form 4: Luebbert Hermann, Director Received 62,500 shares by exercise or conversion
29 Jul 2026	Form 4: Leffler Eugene Frederick, Chief Financial Officer Received 31,250 shares by exercise or conversion
22 Jul 2026	S-8
22 Jul 2026	10-K/A
17 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
14 May 2026	10-Q
14 May 2026	8-K: Results of Operations and Financial Condition
30 Apr 2026	Proxy statement: annual meeting on June 11, 2026
19 Mar 2026	10-K
19 Mar 2026	8-K: Results of Operations and Financial Condition
09 Mar 2026	8-K: Regulation FD Disclosure
06 Mar 2026	Form 4: Weber Kevin Daniel, Director Granted 20,000 Employee stock option (right to buy)
06 Mar 2026	Form 4: Luebbert Hermann, Director Granted 125,000 Restricted Stock Units · Granted 125,000 Employee stock option (right to buy) · Received 137,500 shares by exercise or conversion
06 Mar 2026	Form 4: Leffler Eugene Frederick, Chief Financial Officer Granted 62,500 Restricted Stock Units · Granted 62,500 Employee stock option (right to buy) · Received 87,500 shares by exercise or conversion
06 Mar 2026	Form 4: Lanckriet Heikki, Director Granted 20,000 Employee stock option (right to buy)
06 Mar 2026	Form 4: Hoffman Beth J., Director Granted 20,000 Employee stock option (right to buy)

Comments